Table 3.
Independent baseline predictors of changes in weight and hemoglobin after 2 weeks of atrasentan therapy
| Variable | Linear Regression | Logistic Regression | ||
|---|---|---|---|---|
| Coefficient (95% CI) | P Value | Odds Ratio (95% CI) | P Value | |
| Weight response (≥2 kg weight gain) | ||||
| Atrasentan (0.75 versus placebo) | 0.8 (0.3 to 1.3) | 0.001 | 3.0 (1.0 to 8.5) | 0.04 |
| Atrasentan (1.25 versus placebo) | 1.3 (0.8 to 1.7) | <0.001 | 6.6 (2.3 to 18.6) | <0.001 |
| eGFR (10 ml/min per 1.73 m2) | –0.2 (–0.3 to –0.1) | 0.002 | 0.7 (0.4 to 1.0) | 0.01 |
| HbA1c (%) | 0.2 (0.1 to 0.4) | 0.002 | 1.7 (1.3 to 2.3) | <0.001 |
| Systolic BP (10 mmHg) | 0.1 (0.0 to 0.3) | 0.05 | — | |
| HOMA product (log) | –0.2 (–0.4 to –0.1) | 0.01 | 0.7 (0.5 to 1.0) | 0.03 |
| Hemoglobin response (≥1.3 g/dl hemoglobin fall) | ||||
| Atrasentan (0.75 versus placebo) | –0.7 (–0.9 to –0.5) | <0.001 | — | |
| Atrasentan (1.25 versus placebo) | –1.0 (–1.2 to –0.8) | <0.001 | 5.6 (2.5 to 12.7) | <0.001 |
| eGFR (10 ml/min per 1.73 m2) | 0.1 (0.1 to 0.2) | <0.001 | 0.6 (0.2 to 0.9) | 0.001 |
| Hemoglobin (g/dl) | –0.1 (–0.1 to 0.0) | <0.001 | 1.4 (1.1 to 1.8) | 0.003 |
| Weight (10 kg) | 0.1 (0.0 to 0.1) | 0.01 | 0.9 (0.8 to 1.0) | 0.05 |
The following covariates were included in the initial backward selection model: treatment assignment, age, sex, body weight, hemoglobin, eGFR, albuminuria, systolic BP, eGFR, log-transformed HOMA product, log-transformed B-type natriuretic peptide, thiazide, and loop diuretic use. Systolic BP and atrasentan dose were not included in the final logistic regression models for body weight and hemoglobin, respectively. HbA1c, glycated hemoglobin; HOMA, homeostatic model assessment; 95% CI, 95% confidence interval.